Bjørn Klem, general manager of Oslo Cancer Cluster Incubator, Arild Kristensen, general manager of Smart Care Cluster, and Kathrine Myhre, CEO of Norway Health Tech, look forward to developing the first Norwegian Health Catapult Centre.

Preparing for the first Health Catapult Centre

Bjørn Klem, general manager of Oslo Cancer Cluster Incubator, Arild Kristensen, general manager of Smart Care Cluster, and Kathrine Myhre, CEO of Norway Health Tech, look forward to developing the first Norwegian Health Catapult Centre.

Three leading Norwegian health innovation clusters will collaborate on forming a concept for the first Norwegian Health Catapult Centre.

Siva has selected Oslo Cancer Cluster Incubator, Norway Health Tech and Norwegian Smart Care Cluster to proceed to the next round of the Norwegian Catapult call. The three health clusters are now joining forces to apply for a Health Catapult Centre focusing on precision medicine, patient-centric innovation and health services, medical technology and digital health.

The purpose of a Catapult Centre is to support innovative small to medium-sized companies in Norway on their journey to reach the market. A Catapult Centre helps companies to develop prototypes, test, verify, visualise and simulate – so that ideas can be developed faster, better and with less risk.

By inviting the three health clusters to apply together for a Health Catapult Centre, Siva has shown that health innovation and industrialisation is a crucial part of Norwegian industry and trade. This supports the government’s White Paper on the Health Industry , which calls for the building of a strong Norwegian health industry. The current corona pandemic has also highlighted the importance of local health innovation providers and supporting Norwegian early-stage health companies that can quickly deliver solutions to big societal challenges.

The initial application was submitted last December and deemed successful in February. The main topics of precision medicine, patient-centric innovation and health services, medical technology and digital health will now be discussed further over the next six months in the planning of the final Catapult application. The managers of the three clusters look forward to the opportunity of developing a Health Catapult Centre together.

“By joining forces with two strong complementary Norwegian health clusters, we will strengthen the Catapult application by covering a broader range of services to Norwegian health start-ups and scale-ups. A successful application will enable Oslo Cancer Cluster Incubator to support the growth of Norwegian healthcare start-ups together with public healthcare institutions and international industry,” said Bjørn Klem, general manager of Oslo Cancer Cluster Incubator.

“One of the future key factors for the health industry in Norway to scale in the Norwegian and global market, will be to get access to tools, solutions, data and competence to develop, simulate, test, verify and produce their health products and solutions. The aim of the Health Catapult Centre will be to provide the health industry with these services and collaborative partners for the industry to scale. With the Health Catapult Centre up and running, Norway will also be an attractive partner to international health industry, that needs testing and clinical trials for them to launch new health products and solutions on the global market,” said Kathrine Myhre, CEO of Norway Health Tech.

“Together we stand, divided we fall. The three clusters now have an unique opportunity to provide the booming health industry in Norway with tools and services that will speed their development with higher quality, thus enabling world class solutions faster,” said Arild Kristensen, general manager of Norwegian Smart Care Cluster.

The final application for the Health Catapult Centre will be submitted this autumn. If successful, Oslo Cancer Cluster Incubator, Norway Health Tech and Norwegian Smart Care Cluster will jointly become the first Norwegian Health Catapult Centre.

logos

Photo: Eva Dang / Unsplash

LINK Medical opens new London office

Photo of London by Eva Dang, Unsplash

Our member Link Medical has expanded its organisation with an office in London.

LINK Medical is a full-service contract research organisation that provides product development services for the pharmaceutical and medical device industries across Europe. The company was founded in Norway in 1995 and has since then grown to employ 175 people from various specialist backgrounds, including a specialized oncology team.

Now, LINK Medical’s clinical research services have also expanded to biopharma and medtech in the UK, with an office in London.

LINK Medical CEO, Dr. Ola Gudmundsen says: “We look forward to start building on the competent team already present in the UK to further engage with this important market. We can now offer our customers enhanced service capacity in the UK, helping to drive forward their clinical projects, and thus supporting and improving healthcare for all.”

We are happy that LINK Medical is a part of our cluster organisation and that they are contributing to accelerate the development of cancer treatments.

Sign up to our monthly newsletter

New member: PharmaRelations

Image of Oslo Cancer Cluster Innovation Park

In this series, we will be introducing the new members that have joined our oncology ecosystem in the last six months. Follow us for a new article next week!

Have you heard of PharmaRelations? One of our newest members works with recruiting talents to the Life Sciences.

A cornerstone in the development of cancer treatments is to secure talented professionals to the right jobs. That is why recruitment companies are one of the essential parts of our membership organisation. PharmaRelations is one of the latest additions.

PharmaRelations was founded in Sweden in 1997 and started their recruitment services in 2004. The Oslo office opened in 2018 and their mission is to grow people and companies in Life Science with their portfolio of Talent Services. We talked with Sverre Slaastad, Head of Recruitment and Talent Specialist at PharmaRelations, about why they are involved in Oslo Cancer Cluster.

Could you briefly describe your company and the role it is taking in cancer/health?

“With our extensive network and candidate database, we are the market leader in Life Science recruitment in the Nordic countries. The Life Sciences is our area of expertise, including pharmaceuticals, MedTech, Biotech, Labtech, Animal Health and Dental care,” said Sverre Slaastad.

Why did you join Oslo Cancer Cluster?

“We want to help Oslo Cancer Cluster by recruiting the best people for their members and thereby improving health in society overall,” said Sverre Slaastad.

Pharma relations logo

 

Sign up to our monthly newsletter

Ketil Widerberg, general manager, Oslo Cancer Cluster, supports Abelias proposal to mobilise the health industry in the fight against corona. Photo: Stig Jarnes

Health clusters to help against corona pandemic

Ketil Widerberg, general manager, Oslo Cancer Cluster

Let the health industry contribute to the fight against COVID-19!

This week, Abelia wrote a letter to the Minister of Health and Care Services and the Minister of Trade, Industry and Fisheries, appealing that they use the Norwegian health industry against the corona pandemic.

The corona pandemic has put Norway and its health services in an extraordinary situation. The health industry will play a central role in how this pandemic is handled. There will be a need to think of new ways to deliver health services, in order to alleviate the health sector in the long and short term.

Health tech companies can meet this need by delivering innovative solutions, but we need to utilise this potential quickly and efficiently. A strategic collaboration between the public health services and the up-and-coming health tech companies can achieve this.

Abelia, Oslo Cancer Cluster and the other Norwegian health clusters are uniquely positioned to connect and mobilise members of the health industry. A fast-working advisory council could help to look at the needs the corona crisis creates, to discover innovative solutions, and to identify relevant market opportunities for Norway.

“The corona pandemic has shown the important role the health industry has. Now more than ever, it is crucial to use and understand health data, to implement novel digital solutions in our health services and to speed up drug development times,” said Ketil Widerberg, general manager, Oslo Cancer Cluster.

The proposal in the letter is to assemble an advisory council consisting of representatives from the Norwegian health clusters (Oslo Cancer Cluster, Norway Health Tech, The Life Science Cluster and Norwegian Smart Care Cluster) in close collaboration with the governmental funding bodies (Innovation Norway, the Research Council of Norway and SIVA).

Sign up to our monthly newsletter